AbbVie stock is up 18% since the start of the year and it has gained around 62% from its March lows. Despite the recent rally, AbbVie could offer an upside in the near term, as the company’s revenues in the last three quarters have grown by 30%, primarily aided by the Allergan acquisition…
Source: Forbes Markets
